Idera Pharmaceuticals, Inc. (IDRA)
Stock Price:
$2.04 USD
-0.09 (-4.23%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed
After-hours: $1.92 -0.12 (-5.88%) Aug 4, 7:41 PM
Key Info
| Market Cap |
68.90M |
| Revenue (ttm) |
1.45M |
| Net Income (ttm) |
-36.72M |
| Shares Out |
34.53M |
| EPS (ttm) |
-2.27 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 4, 2020 |
| Last Price |
$2.04 |
| Previous Close |
$2.13 |
| Change ($) |
-0.09 |
| Change (%) |
-4.23% |
| Day's Open |
2.13 |
| Day's Range |
2.00 - 2.14 |
| Day's Volume |
175,708 |
| 52-Week Range |
0.81 - 3.58 |
More Stats
| Market Cap |
68.90M |
| Enterprise Value |
36.44M |
| Earnings Date (est) |
Aug 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
34.53M |
| Float |
24.93M |
| EPS (basic) |
-2.3 |
| EPS (diluted) |
-2.27 |
| FCF / Share |
-1.38 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
425,941 |
| Short Ratio |
2.41 |
| Short % of Float |
1.57% |
| Beta |
2.10 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
47.59 |
| PB Ratio |
1.24 |
| Revenue |
1.45M |
| Operating Income |
-47.84M |
| Net Income |
-36.72M |
| Free Cash Flow |
-41.90M |
| Net Cash |
32.47M |
| Net Cash / Share |
0.96 |
| Gross Margin |
-1,663.74% |
| Operating Margin |
-3,304.07% |
| Profit Margin |
-4,472.90% |
| FCF Margin |
-2,893.65% |
| ROA |
-60.30% |
| ROE |
-132.27% |
| ROIC |
258.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
5 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$7.60*
(272.55% upside)
Low
5.00
Current: $2.04
High
10.00
Target: 7.60
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 1.45 | 0.66 | 0.90 | 16.20 | 0.25 | 0.07 | 0.05 | 0.05 | 0.05 | 16.11 |
| Revenue Growth | 118.73% | -26.61% | -94.43% | 6405.62% | 241.1% | 55.32% | -7.84% | -3.77% | -99.67% | - |
| Gross Profit | 1.45 | 0.66 | 0.90 | 16.20 | 0.25 | 0.07 | 0.05 | 0.05 | 0.05 | 16.11 |
| Operating Income | -46.07 | -60.96 | -66.47 | -38.76 | -48.85 | -38.75 | -18.17 | -19.90 | -25.86 | -17.98 |
| Net Income | -56.52 | -59.88 | -65.98 | -38.39 | -48.56 | -38.64 | -18.23 | -19.24 | -23.78 | -17.96 |
| Shares Outstanding | 28.55 | 26.60 | 19.68 | 15.95 | 14.39 | 10.35 | 5.49 | 3.45 | 3.45 | 3.14 |
| Earnings Per Share | -2.96 | -2.25 | -3.35 | -2.41 | -3.36 | -3.76 | -3.84 | -6.48 | -8.24 | -5.68 |
| Operating Cash Flow | -44.50 | -51.92 | -55.26 | -28.20 | -42.99 | -31.32 | -17.14 | -19.92 | -19.19 | -19.56 |
| Capital Expenditures | - | 0.22 | -0.21 | -0.41 | -0.73 | -1.09 | -0.01 | - | -0.02 | -0.09 |
| Free Cash Flow | -44.50 | -51.70 | -55.47 | -28.61 | -43.71 | -32.41 | -17.15 | -19.92 | -19.22 | -19.65 |
| Cash & Equivalents | 42.79 | 71.43 | 113 | 109 | 60.16 | 41.23 | 29.40 | 10.41 | 24.88 | 34.95 |
| Total Debt | 1.06 | - | 0.21 | 0.50 | 0.76 | 0.87 | - | - | - | - |
| Net Cash / Debt | 41.73 | 71.43 | 112 | 109 | 59.40 | 40.36 | 29.40 | 10.41 | 24.88 | 34.95 |
| Assets | 47.49 | 73.02 | 118 | 113 | 92.28 | 51.43 | 36.87 | 10.82 | 25.60 | 36.88 |
| Liabilities | 58.66 | 9.03 | 10.72 | 9.88 | 8.69 | 8.02 | 4.42 | 4.20 | 7.65 | 3.78 |
| Book Value | -11.17 | 63.99 | 108 | 103 | 83.58 | 43.40 | 32.45 | 0.71 | 12.02 | 33.10 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Idera Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
36 |
| CEO |
Vincent J. Milano |
Stock Information
| Ticker Symbol |
IDRA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: IDRA |
| IPO Date |
January 24, 1996 |
Description
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer. The company was founded in 1989 and is based in Exton, Pennsylvania.